

FORM 3

UNITED STATES SECURITIES AND EXCHANGE
COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES

OMB APPROVAL

OMB Number: 3235-0104
 Estimated average burden
 hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>GLAXOSMITHKLINE PLC</u> (Last) (First) (Middle) <u>980 GREAT WEST ROAD</u> (Street) <u>BRENTFORD X0 TW8 9GS</u> <u>MIDDLESEX</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/29/2021</u>	3. Issuer Name and Ticker or Trading Symbol <u>CVRx, Inc. [CVRX]</u> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person
--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series B-2 Preferred Stock	(1)	(1)	Common Stock	1,505 ⁽²⁾	(1)	I	See footnote ⁽⁸⁾
Series C-2 Preferred Stock	(3)	(3)	Common Stock	12,979 ⁽²⁾	(3)	I	See footnote ⁽⁸⁾
Series D-2 Preferred Stock	(4)	(4)	Common Stock	14,917 ⁽²⁾	(4)	I	See footnote ⁽⁸⁾
Series E-2 Preferred Stock	(5)	(5)	Common Stock	8,380 ⁽²⁾	(5)	I	See footnote ⁽⁸⁾
Series F-2 Preferred Stock	(6)	(6)	Common Stock	27,345 ⁽²⁾	(6)	I	See footnote ⁽⁸⁾
Series G Preferred Stock	(7)	(7)	Common Stock	635,646 ⁽²⁾	(7)	I	See footnote ⁽⁸⁾

Explanation of Responses:

- The shares of Series B-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series B-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- Share numbers give effect to the reverse split of each share of the Issuer's Common Stock into 0.025857287 shares of Common Stock, effected on June 22, 2021, which will be effective for the Preferred Stock upon its conversion to Common Stock upon the closing of the Issuer's initial public offering.
- The shares of Series C-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series C-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares of Series D-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series D-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares of Series E-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series E-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares of Series F-2 Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series F-2 Preferred Stock will automatically convert into 0.025857287 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares of Series G Preferred Stock are convertible at any time at the election of the holder without payment of further consideration. Each share of Series G Preferred Stock will automatically convert into 0.0632143218 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares have no expiration date.
- The shares reported herein are held of record by Action Potential Venture Capital, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc (the "Reporting Person").

Victoria Whyte,
Authorized Signatory,
GlaxoSmithKline plc

07/06/2021

** Signature of Reporting
 Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

